Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
about
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisInterventions for skin reactions associated with targeted anticancer treatmentsInterventions for skin reactions associated with targeted anticancer treatmentsA phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabCutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsExpert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UKOverview and management of dermatologic events associated with targeted therapies for medullary thyroid cancerNovel immunotherapeutic strategies of gastric cancer treatmentVandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Cutaneous complications of molecular targeted therapy used in oncologyAcneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New InsightsGemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysisCutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 PatientsRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerHealth-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.Skin care management in cancer patients: an evaluation of quality of life and tolerability.Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer.Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Unilateral onycholysis in a patient taking erlotinib (Tarceva).Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.Tyrosine kinase inhibitors in lung cancer.Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib.Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendationsGraphene-based platforms for cancer therapeuticsPhase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic ResponseDaily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.
P2860
Q21133732-823E976E-6C25-42CA-9867-2EE6B2B49ABFQ24187823-8010CB97-F71F-445A-B21E-5D934CF04729Q24235777-F9A4C94B-DF56-4B45-ABFB-388A70F791F3Q24594725-A1037035-D011-4111-B034-9BD84FBF9458Q26781472-4F63E422-3F74-44F4-BDD9-D9255D7AAB21Q26799390-BC69B3B0-607B-4D89-83F2-FAA92F61AB87Q27005701-98B66AD1-934F-4D5E-A669-13A3B486FA0AQ27011232-B8FA1E79-5E0D-4413-80FE-D91BFA0EE15FQ27692050-EFE89810-258C-4646-ABCB-740593F685C8Q28070095-4A234D3C-CB3C-4786-ADA1-9A78ED378368Q28081446-72AED31A-340E-4AD2-B88B-40C654E4BB1CQ28487656-06E0766B-9EDE-47C8-AB88-925DB538D73AQ29248067-3C4E3DF4-124D-4B54-A6D1-E5317C816C34Q30248499-317BA40D-F70C-4ABC-A55C-055372CE2BA2Q33410375-CAF48083-EE6B-4049-A2FC-1A95AEC47CB0Q33885559-B0268D80-68FA-4320-8939-9D4D7C741418Q33983656-2A97ADF7-5354-437F-B9E1-406EDBE9239FQ34508065-279DBD22-C1CE-4F0F-937C-8E96EBF00798Q34700294-EA9DEB64-D448-49B0-B1D2-17015E0A72ECQ35026998-EC8E973B-2848-47A9-9397-58F1E690AD31Q35031831-8765A5D0-9322-4D0D-A00C-734C0449622BQ35034768-1CFC88E6-44D8-4C11-BA9F-329B281A00B8Q35171463-A90F4B1A-E19D-4774-9AC0-3129BCC26589Q35584288-D95A2B47-955D-4312-B5BF-E1A8059D2FBDQ35908430-C745F200-3082-4E38-AFA6-8B29EFFEB55FQ36246406-212778C1-6B92-4764-BBE0-5D68BBDF9867Q36537873-AFAA921A-E0DA-4330-A73E-7389857882BBQ36951089-9E4821BE-BF37-4AE2-9B3E-26F95629D165Q37011694-80231D2D-B1AA-4B1F-A777-03F1917372A0Q37033958-3EBB34C0-D69C-466E-B32E-E7DB3F9F192DQ37050472-61FDA931-24F1-4F6E-A609-441184616FEAQ37102073-2B9B88E8-4B6D-48F3-B1B1-0A7D1B05C613Q37158662-0B4CF8B0-60E0-4B01-9947-F69D556D4D41Q37196491-ECEEF634-D9D6-42A3-9DE2-061F5DD836F1Q37390753-2BB69E61-2A56-4016-90B9-4FACC3431168Q37442683-A6971ACC-A3AB-4252-9DD5-88A99B0CBA71Q37597811-F96E5949-9A13-4F98-80DC-E5E637BDA76AQ37645161-2AA85E1D-62F2-4E21-8143-DEEEF15AF2F2Q37653001-1C3EF08F-59F5-40C7-8228-3898F0FB5EE3Q37780040-47928627-7E40-43D9-B0F9-49524BDCE548
P2860
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Epidermal growth factor recept ...... radigm in clinical management.
@en
type
label
Epidermal growth factor recept ...... radigm in clinical management.
@en
prefLabel
Epidermal growth factor recept ...... radigm in clinical management.
@en
P2093
P1433
P1476
Epidermal growth factor recept ...... aradigm in clinical management
@en
P2093
Jody Garey
Thomas J Lynch
P304
P356
10.1634/THEONCOLOGIST.12-5-610
P577
2007-05-01T00:00:00Z